dnay - DNAY STOCK NEWS

SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Codex DNA, a leader in automated synthetic biology systems, announces that CEO Todd R. Nelson, PhD, will present virtually at the 42^nd Annual Cowen Healthcare Conference on March 9^th at 2:10 pm ET. He will also participate in a panel on Synthetic Biology Enabling Technologies on March 7^th at 10:30 am ET. Both events will be live-webcasted, with replays available for 30 days post-event. Codex DNA innovates in rapid and accurate DNA/RNA synthesis for various markets, enhancing scientific research worldwide.

Codex DNA (Nasdaq: DNAY) announced participation in the SVB Leerink 11th Annual Global Healthcare Conference on February 9, 2022. An updated corporate presentation will be available on February 16, 2022, at 12:00 PM ET / 9:00 AM PT. This presentation can be accessed via the investors section of the Codex DNA website.

As a leader in synthetic biology, Codex DNA provides innovative solutions, including the award-winning BioXp™ system, revolutionizing DNA and mRNA synthesis for applications in precision medicine, drug discovery, and more.

Codex DNA (NASDAQ: DNAY) announces the successful construction of H1 and N1 genes from the influenza A virus using its proprietary SOLA enzymatic DNA synthesis technology. This method aims to provide significant quality, time, and cost advantages over traditional synthesis methods, facilitating the production of DNA, RNA, and proteins for mRNA-based vaccines and therapeutics. The technology, integrated into the BioXp systems, is expected to enhance efficiency and scalability while reducing the environmental impact by minimizing toxic chemical usage.

Codex DNA (NASDAQ: DNAY) has entered a strategic collaboration with Pfizer for early access to its enzymatic DNA synthesis technology, SOLA EDS. This agreement could generate milestone payments exceeding $100 million, contingent on successful product development and commercialization. Codex DNA aims to enhance vaccine and biotherapeutic R&D efficiency through its technology, which accelerates synthetic DNA and RNA construction. The partnership validates Codex DNA's innovative solutions and aims to address major medical challenges by integrating SOLA EDS into future instrumentation.

Codex DNA has launched a new full-length synthetic genome of the SARS-CoV-2 virus for the Omicron variant, enhancing global research capabilities for diagnostics, treatments, and vaccines.

Utilizing the BioXp™ 3250 system, this release allows labs worldwide to generate virus strains for effective responses. Codex DNA now offers a total of 14 synthetic genomes, supporting researchers in addressing pandemic challenges. All genomes are produced in the U.S. and are subject to strict biosecurity screening for responsible use.

Codex DNA, Inc. (NASDAQ: DNAY) has launched its BioXp™ mRNA synthesis kits featuring CleanCap® Reagent AG technology from TriLink BioTechnologies. This new automation solution enables the production of high-quality, capped mRNA efficiently, addressing challenges in mRNA-based vaccine and therapy development that were highlighted by the COVID-19 pandemic. Users can generate up to 16 active mRNA constructs with 10 micrograms each in a single automated run, significantly reducing turnaround times. Key presentations on mRNA advancements will occur at upcoming conferences from November 30 to December 2, 2021.

SAN DIEGO, Nov. 11, 2021 – Codex DNA, a leader in automated synthetic biology, announced its CEO, Todd R. Nelson, will present at the 12th Annual Jefferies London Healthcare Conference. The pre-recorded session will be available on November 18 at 5:00 PM GMT / 12:00 PM ET / 9:00 AM PT. The presentation can be accessed on Codex DNA's investor website, with an archived replay available for 30 days post-event. The company focuses on innovative solutions in synthetic biology, utilizing their BioXp™ system for rapid DNA/RNA synthesis.

Codex DNA, Inc. (NASDAQ: DNAY) reported third-quarter 2021 results with revenue of $2.8 million, a 70% increase from $1.6 million year-over-year. The surge is attributed to new product sales and increased royalties. Operating expenses rose to $10.6 million, up from $5.2 million, mainly due to headcount expansion. The net loss was $9.8 million, compared to $4.5 million in the previous year, resulting in a net loss per share of $0.34. Cash and cash equivalents stood at $109.8 million as of September 30, 2021, with $14.6 million in debt outstanding.

Codex DNA, Inc. (DNAY) has announced the acquisition of Eton Bioscience for approximately $13 million. This strategic move aims to enhance Codex DNA's BioXp™ system and biofoundry services, reducing raw material costs and accelerating growth. Eton generated $5.1 million in revenue during the first nine months of 2021 and is expected to contribute positively post-acquisition. However, Codex anticipates a slight dilution in earnings per share for 2022 before becoming accretive thereafter.